All canine diagnoses

Your dog was diagnosed with Oral Squamous Cell Carcinoma. Second most common oral tumour after melanoma. Biological behaviour varies dramatically by location: rostral/gingival SCC has low metastatic rate and good surgical prognosis; tonsillar SCC is highly metastatic with poor prognosis. Compare 4 treatment options for dogs including Mandibulectomy / Maxillectomy (Surgical Excision), Surgery + Adjuvant Radiation, Tonsillar SCC — Radiation ± Chemotherapy — with survival times, costs, and what to expect during treatment.

🐕

Oral Squamous Cell Carcinoma

WHO TNM staging

BreedsLarge breeds generallyStandard PoodleLabrador RetrieverGolden Retriever
canine

Epithelial

About This Cancer

Oral squamous cell carcinoma (SCC) arises from the squamous epithelial cells that line the surfaces of the mouth. Its behaviour varies dramatically depending on location within the oral cavity: tumours in the front of the mouth (rostral gingival SCC) tend to invade bone locally but rarely spread distantly, giving them a good prognosis with surgical removal. In stark contrast, tonsillar SCC is one of the most aggressive oral tumours in dogs, with early and widespread metastasis to lymph nodes and lungs and a very poor prognosis. Tumours at intermediate locations fall somewhere between these extremes. This location-dependent behaviour is a defining feature of oral SCC and directly guides treatment recommendations — what works well for a gingival tumour may not be appropriate for a tonsillar one.

WHO TNM for Canine Oral Tumours

Based on tumour size, lymph node status, and metastasis

Stage T1Tumour <2 cm maximum diameter
Stage T2Tumour 2-4 cm
Stage T3Tumour >4 cm
Stage N0No regional LN metastasis
Stage N1Ipsilateral LN metastasis
Stage N2Bilateral LN metastasis
Prognostic Factors(3)
Location (rostral vs caudal vs tonsillar)Rostral non-tonsillar: MST 20-46 months with surgery. Caudal: harder to resect, worse outcomes. Tonsillar: MST 3-12 months, highly metastatic.(Kosovsky et al., 1991)
Bone invasionNon-tonsillar SCC with bone invasion still carries good surgical prognosis if mandibulectomy/maxillectomy achieves clean margins.
Tonsillar locationTonsillar SCC is a biologically distinct entity — >70% have metastasis at diagnosis. Should be considered separately from other oral SCC.(Brooks et al., 1988)
Minimum Workup(5 steps)
1Incisional biopsy for histological confirmation
2CT scan of head (assess bone invasion, surgical margins, LN)
3Regional lymph node FNA (mandibular, retropharyngeal)
4Thoracic radiographs (3-view)
5Complete blood count and biochemistry

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Mandibulectomy / Maxillectomy (Surgical Excision)
~26 mo (20–46)
Surgery + Adjuvant Radiation
~20 mo (14–36)
Tonsillar SCC — Radiation ± Chemotherapy
~5 mo (3–12)
Palliation (NSAIDs + Pain Management)
~3 mo (1–6)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.